Shares of Vernalis plc (NASDAQ:VNLPY) have been given an average broker rating score of 3.00 (Hold) from the one analysts that provide coverage for the company, Zacks Investment Research reports. One investment analyst has rated the stock with a hold recommendation.

Zacks has also given Vernalis plc an industry rank of 104 out of 265 based on the ratings given to its competitors.

Separately, Zacks Investment Research downgraded shares of Vernalis plc from a “hold” rating to a “sell” rating in a report on Tuesday, July 25th.

Shares of Vernalis plc (NASDAQ:VNLPY) remained flat at $0.58 during mid-day trading on Thursday. The stock’s market cap is $152.64 million. The stock’s 50 day moving average is $0.58 and its 200-day moving average is $0.58. Vernalis plc has a 12 month low of $0.47 and a 12 month high of $0.95.

TRADEMARK VIOLATION WARNING: “Vernalis plc (VNLPY) Receives Consensus Rating of “Hold” from Brokerages” was reported by American Banking News and is owned by of American Banking News. If you are accessing this report on another website, it was copied illegally and republished in violation of international trademark and copyright legislation. The legal version of this report can be read at https://www.americanbankingnews.com/2017/09/07/vernalis-plc-vnlpy-receives-consensus-rating-of-hold-from-brokerages.html.

Vernalis plc Company Profile

Vernalis plc is a commercial-stage pharmaceutical company. The Company is engaged in the research, development and commercialization of pharmaceutical products. The Company operates through two segments: Commercial, which covers all areas relating to the commercial sale of pharmaceutical products, the manufacture and distribution directly related to that activity, and Research and Development, which includes all activities related to the research and development of pharmaceutical products for a range of medical disorders.

Get a free copy of the Zacks research report on Vernalis plc (VNLPY)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Vernalis plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vernalis plc and related companies with MarketBeat.com's FREE daily email newsletter.